In particular, more than 90% of pancreatic ductal adenocarcinomas have KRAS mutations, which indicates the essential incorporation of aberrations in the RAS signaling pathway in pancreatic cancer. Here, KRAS is linked to pancreatic ductal adenocarcinoma.